Fate Therapeutics (FATE) Receivables - Accured (2019 - 2026)
Fate Therapeutics (FATE) posted Receivables - Accured of $800000.0 for Q1 2026, up 14.29% on a QoQ basis from $700000.0 in Q4 2025, and down 60.0% year-over-year from $2.0 million in Q1 2025.
Fate Therapeutics (FATE) Receivables - Accured (2019 - 2026) Analysis & Trends
Fate Therapeutics' Receivables - Accured history runs 8 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- Quarterly Receivables - Accured fell 60.0% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $800000.0 (down 60.0% YoY) and the FY2025 annual result came in at $700000.0, down 66.67% from the prior year.
- Receivables - Accured was $800000.0 for Q1 2026 at Fate Therapeutics, up from $700000.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $2.1 million in Q4 2024 and bottomed at $1000.0 in Q2 2022.
- A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Receivables - Accured.
- Annual changes were most pronounced in 2022 — Receivables - Accured slumped 99.95% — and 2024, when it surged 154445.45%.
- Fate Therapeutics' Receivables - Accured stood at $800000.0 in 2022, then gained by 12.5% to $900000.0 in 2023, then surged by 133.33% to $2.1 million in 2024, then plunged by 66.67% to $700000.0 in 2025, then gained by 14.29% to $800000.0 in 2026.
- Business Quant data shows FATE's Receivables - Accured at $800000.0 in Q1 2026, $700000.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.53 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 900,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |